Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English
  • Spanish

Education

Undergraduate School

Harvard University

Cambridge, MA

Medical School

Yale University School of Medicine

New Haven, CT

Internship

Boston Combined Residency Program (BCRP)

Boston, MA

Residency

Boston Combined Residency Program (BCRP)

Boston, MA

Fellowship

Pediatric Rheumatology

Boston Children's Hospital

Boston, MA

Certifications

  • American Board of Pediatrics (General)
  • American Board of Pediatrics (Rheumatology)

Professional History

Dr. Hazen is a graduate of Harvard University and the Yale School of Medicine and completed her pediatric residency and rheumatology fellowship training at the Boston Children's Hospital where she has remained on faculty as a pediatric Division of General Pediatrics and rheumatology attending. Dr. Hazen's clinical practice is devoted to the care of complex patients, including hospitalized children and children with immune-mediated illness. She is the co-founder and co-director of a multidisciplinary clinic, the MAID clinic, devoted the the care of and improving the understanding of children with monogenic immune dysregulatory syndromes. She is the director of quality improvement for the Rheumatology Program and is the site PI for a national pediatric rheumatology quality improvement collaborative, PR-COIN. She is interested in the intersection of pediatric Division of General Pediatrics, rheumatology, and quality improvement, and she has co-developed clinical practice guidelines for the care of patients with rheumatic disease (eg HLH/MAS, KD, FUO) for use by hospitalists and sub-specialists.

Publications

  1. Sex Differences in B Cells From the Joints of Children With Oligoarticular Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2025 Mar 17. View Abstract

  2. Multidisciplinary approach to treating complex immune dysregulation disorders: an adaptive model for institutional implementation. Front Immunol. 2025; 16:1519955. View Abstract

  3. Universal health-related social needs screening in a paediatric rheumatology clinic. Rheumatol Adv Pract. 2025; 9(2):rkaf014. View Abstract

  4. Using a collaborative learning health system approach to improve disease activity outcomes in children with juvenile idiopathic arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network. Front Pediatr. 2024; 12:1434074. View Abstract

  5. Pediatric Rheumatology Care and Outcomes Improvement Network's Quality Measure Set to Improve Care of Children With Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2023 12; 75(12):2442-2452. View Abstract

  6. Incidence and Risk Factors for Eosinophilia and Lung Disease in Biologic-Exposed Children With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2023 10; 75(10):2063-2072. View Abstract

  7. Disordered T cell-B cell interactions in autoantibody-positive inflammatory arthritis. Front Immunol. 2022; 13:1068399. View Abstract

  8. Dr. Degar et al reply. J Rheumatol. 2023 07; 50(7):968-969. View Abstract

  9. Longitudinal assessment of preparation for care transition among adolescents and young adults with rheumatologic disease: a single-center pilot study. Pediatr Rheumatol Online J. 2022 Oct 21; 20(1):93. View Abstract

  10. An Evidence-Based Guideline Improves Outcomes for Patients With Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome. J Rheumatol. 2022 Sep; 49(9):1042-1051. View Abstract

  11. Consensus Approach to a Treat-to-target Strategy in Juvenile Idiopathic Arthritis Care: Report From the 2020 PR-COIN Consensus Conference. J Rheumatol. 2022 05; 49(5):497-503. View Abstract

  12. Proteomics based markers of clinical pain severity in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2022 Jan 15; 20(1):3. View Abstract

  13. Vestibular Evaluation and Management of Children with Sensorineural Hearing Loss. Otolaryngol Clin North Am. 2021 Dec; 54(6):1241-1251. View Abstract

  14. Th1 polarization defines the synovial fluid T cell compartment in oligoarticular juvenile idiopathic arthritis. JCI Insight. 2021 09 22; 6(18). View Abstract

  15. A multidisciplinary assessment of pain in juvenile idiopathic arthritis. Semin Arthritis Rheum. 2021 08; 51(4):700-711. View Abstract

  16. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020 11 02; 130(11):5942-5950. View Abstract

  17. Vasculitis as a Major Morbidity Factor in Patients With Partial RAG Deficiency. Front Immunol. 2020; 11:574738. View Abstract

  18. Providing Inpatient Medical Care to Children With Autism Spectrum Disorder. Hosp Pediatr. 2020 10; 10(10):918-924. View Abstract

  19. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020 07; 72(7):1059-1063. View Abstract

  20. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. JCI Insight. 2020 03 26; 5(6). View Abstract

  21. The immunologic features of patients with early-onset and polyautoimmunity. Clin Immunol. 2020 02; 211:108326. View Abstract

  22. Defining a new immune deficiency syndrome: MAN2B2-CDG. J Allergy Clin Immunol. 2020 03; 145(3):1008-1011. View Abstract

  23. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019 12; 78(12):1722-1731. View Abstract

  24. Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency. J Allergy Clin Immunol Pract. 2019 Jul - Aug; 7(6):1970-1985.e4. View Abstract

  25. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019 Feb 14; 17(1):7. View Abstract

  26. Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases. Ann Rheum Dis. 2017 04; 76(4):765-772. View Abstract

  27. Next-Generation Sequencing Reveals Restriction and Clonotypic Expansion of Treg Cells in Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2016 07; 68(7):1758-68. View Abstract

  28. Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia. J Exp Med. 2015 Jun 01; 212(6):939-51. View Abstract

  29. Trainee and program director perceptions of quality improvement and patient safety education: preparing for the next accreditation system. Clin Pediatr (Phila). 2014 Nov; 53(13):1248-54. View Abstract

  30. Expanding the spectrum of recombination-activating gene 1 deficiency: a family with early-onset autoimmunity. J Allergy Clin Immunol. 2013 Oct; 132(4):969-71.e1-2. View Abstract

  31. A taste of periodic fever syndromes. Pediatr Emerg Care. 2013 Jul; 29(7):842-8; quiz 849-51. View Abstract

  32. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013 May; 65(5):745-52. View Abstract

  33. Multiple juvenile idiopathic arthritis subtypes demonstrate proinflammatory IgG glycosylation. Arthritis Rheum. 2012 Sep; 64(9):3025-33. View Abstract

  34. Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis. Arthritis Res Ther. 2012 Mar 05; 14(2):R43. View Abstract

  35. Regulation of human neutrophil Fc? receptor IIa by C5a receptor promotes inflammatory arthritis in mice. Arthritis Rheum. 2011 Feb; 63(2):467-78. View Abstract

  36. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010 Aug; 62(8):2239-48. View Abstract

  37. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2008 Feb; 58(2):567-70. View Abstract

  38. Mutations of the HLH-associated gene UNC13D (MUNC13-4) in a patient with systemic juvenile idiopathic arthritis. Arthritis and Rheumatism. 2008; 58:567-570.

  39. Mutations of the HLH-associated gene UNC13D (MUNC13-4) in a patient with systemic juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting. 2007.

  40. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. Journal of Clinical Investigation. 2005; 115:1177-1187.

  41. Escape from Immune Surveillance Does Not Result in Tolerance to Tumor-Associated Antigens. Journal of Immunotherapy. 2004; 27:329.

  42. Characterization of the Immune Responses to the Tumor-Associated HY-Antigen. 2002.

  43. Progressive Tumor Growth in a Model Tumor Antigen System Does Not Induce Immunologic Tolerance but Appears to Induce Weak Immunity Toward Tumor Antigens. American Society of Hematology Meeting. 2001.
BESbswy